ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
In VivoWhere therapeutic innovations have historically lagged, Freya Biosciences is developing novel microbiome-based treatments that could transform women’s reproductive health. Founded by a team of eight c
ScripChina’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Looks Into Tolerizing Vaccines,